Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Equity Ratio (2016 - 2026)

Gyre Therapeutics has reported Equity Ratio over the past 16 years, most recently at 0.86 for Q4 2025.

  • Quarterly Equity Ratio rose 69.62% to 0.86 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.86 through Dec 2025, up 69.62% year-over-year, with the annual reading at 0.86 for FY2025, 69.62% up from the prior year.
  • Equity Ratio was 0.86 for Q4 2025 at Gyre Therapeutics, up from 0.64 in the prior quarter.
  • Over five years, Equity Ratio peaked at 8.56 in Q3 2023 and troughed at 0.12 in Q4 2023.
  • The 5-year median for Equity Ratio is 0.84 (2021), against an average of 1.6.
  • Year-over-year, Equity Ratio soared 804.18% in 2023 and then crashed 90.82% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 1.07 in 2021, then decreased by 20.24% to 0.85 in 2022, then crashed by 85.95% to 0.12 in 2023, then soared by 321.84% to 0.5 in 2024, then surged by 69.62% to 0.86 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Equity Ratio are 0.86 (Q4 2025), 0.64 (Q3 2025), and 0.85 (Q2 2025).